IPM Take
AMR policy often gets trapped between two incomplete messages: use fewer antibiotics, or create more antibiotics. The updated WHO plan is stronger because it puts prevention, stewardship, access, surveillance, innovation and One Health governance into the same frame. The political challenge is to avoid a false choice. Access without stewardship accelerates resistance. Stewardship without access leaves patients untreated. The next decade must build systems that can do both.
Executive Summary
On 25 May 2026, WHO announced that Member States at the Seventy-ninth World Health Assembly had adopted the updated Global Action Plan on Antimicrobial Resistance for 2026 to 2036. The plan provides a One Health framework for coordinated global, regional and national action across human health, animal health, plants, food systems and the environment. It emphasises prevention-first interventions, including infection prevention and control, water, sanitation and hygiene, vaccination, biosecurity and environmental measures, alongside responsible antimicrobial use, surveillance, innovation and sustainable financing.
Why it matters
- Policymakers: Need to finance national AMR plans, not only endorse global commitments.
- Clinicians / hospitals: Need diagnostics, stewardship teams, infection control and reliable access to quality-assured antimicrobials.
- Industry / innovation partners: Need clearer incentives for antibiotic, diagnostic and manufacturing innovation that supports both access and responsible use.
Previously, AMR policy often moved in separate lanes. One lane focused on antimicrobial stewardship and reducing inappropriate use. Another focused on the thin antibiotic pipeline. A third focused on access gaps, especially in low- and middle-income countries where people may still die because effective treatment is unavailable.
The updated WHO plan connects these problems. It frames AMR as a One Health threat and sets out a decade-long agenda for countries to update, finance and monitor national action plans. The draft plan states that countries need stronger capacity, financing and coordination to prioritise, cost, implement and monitor multisectoral AMR action plans. It also explicitly links AMR action to equitable access to antimicrobials, vaccines and diagnostic tools.
The affected population is global, but the equity issue is sharpest where diagnostic access, regulatory capacity, quality-assured medicines and infection prevention infrastructure are weakest. A patient with sepsis does not benefit from stewardship if the right antibiotic is unavailable. A patient receiving unnecessary antibiotics does not benefit from access if resistance is being accelerated.
For IPM, AMR is precision public health in its most practical form: the right antimicrobial, guided by the right diagnostic, delivered to the right patient, under governance that protects future effectiveness. The next policy test is implementation, not language.
